1. Home
  2. AVXL

AVXL

Anavex Life Sciences Corp.

Logo Anavex Life Sciences Corp.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-19-2024 2:31pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.

Founded: N/A Country:
United States
United States
Employees: 40 City: NEW YORK
Market Cap: 312.0M IPO Year: N/A
Target Price: $40.00 AVG Volume (30 days): 1.3M
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.55 EPS Growth: N/A
52 Week Low/High: $4.16 - $10.45 Next Earning Date: 05-07-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: